Mediford

Mediford Corporation is a Japanese subsidiary of PHC Holdings Corporation (Tokyo Stock Exchange code: 6523). In November 2023, as a member of the PHC Group, the company began focusing on drug development support services as its core business. Mediford Corporation provides comprehensive services for drug development, ranging from the research and discovery phase to the clinical development phase. Mediford Corporation is committed to strengthening its services for global pharmaceutical companies and analytical laboratories by collaborating with pharmaceutical/biotech companies and academia in advanced scientific fields, utilizing analytical technologies required for non-clinical and clinical studies to advance emerging therapeutic approaches.